These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29396508)

  • 1. Elevated miR-301a expression indicates a poor prognosis for breast cancer patients.
    Zheng JZ; Huang YN; Yao L; Liu YR; Liu S; Hu X; Liu ZB; Shao ZM
    Sci Rep; 2018 Feb; 8(1):2225. PubMed ID: 29396508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer.
    Cao ZG; Li JJ; Yao L; Huang YN; Liu YR; Hu X; Song CG; Shao ZM
    Oncotarget; 2016 Oct; 7(40):64900-64909. PubMed ID: 27588500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer.
    Yu H; Li H; Qian H; Jiao X; Zhu X; Jiang X; Dai G; Huang J
    Med Oncol; 2014 Nov; 31(11):283. PubMed ID: 25311065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miRNA-135b Contributes to
    Uva P; Cossu-Rocca P; Loi F; Pira G; Murgia L; Orrù S; Floris M; Muroni MR; Sanges F; Carru C; Angius A; De Miglio MR
    Int J Med Sci; 2018; 15(6):536-548. PubMed ID: 29725243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer.
    Jang MH; Kim HJ; Gwak JM; Chung YR; Park SY
    Hum Pathol; 2017 Oct; 68():69-78. PubMed ID: 28882698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-493 is a prognostic factor in triple-negative breast cancer.
    Yao L; Liu Y; Cao Z; Li J; Huang Y; Hu X; Shao Z
    Cancer Sci; 2018 Jul; 109(7):2294-2301. PubMed ID: 29777630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence.
    Nam RK; Benatar T; Wallis CJ; Amemiya Y; Yang W; Garbens A; Naeim M; Sherman C; Sugar L; Seth A
    Prostate; 2016 Jul; 76(10):869-84. PubMed ID: 26990571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer.
    García-Vazquez R; Ruiz-García E; Meneses García A; Astudillo-de la Vega H; Lara-Medina F; Alvarado-Miranda A; Maldonado-Martínez H; González-Barrios JA; Campos-Parra AD; Rodríguez Cuevas S; Marchat LA; López-Camarillo C
    Tumour Biol; 2017 Jun; 39(6):1010428317702899. PubMed ID: 28621239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation.
    Dong G; Liang X; Wang D; Gao H; Wang L; Wang L; Liu J; Du Z
    Med Oncol; 2014 Jul; 31(7):57. PubMed ID: 24930006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer.
    Zeng Z; Chen X; Zhu D; Luo Z; Yang M
    Yonsei Med J; 2017 Jul; 58(4):697-702. PubMed ID: 28540980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
    Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
    Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
    Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
    Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-4417 is a tumor suppressor and prognostic biomarker for triple-negative breast cancer.
    Wong CK; Gromisch C; Ozturk S; Papageorgis P; Abdolmaleky HM; Reinhard BM; Thiagalingam A; Thiagalingam S
    Cancer Biol Ther; 2019; 20(8):1113-1120. PubMed ID: 30922194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma.
    Lan F; Qing Q; Pan Q; Hu M; Yu H; Yue X
    Cell Oncol (Dordr); 2018 Feb; 41(1):25-33. PubMed ID: 29076027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
    Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
    PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulation of microRNAs in triple-negative breast cancer.
    Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I
    Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
    Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
    Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.